MedTrace Logo

EIT Evaluation of Different Antihypertensive Agents on the Ventilation-Perfusion Ratio in Patients With Acute Respiratory Failure

NCT07603037 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-22

No results posted yet for this study

Summary

his prospective, single-center interventional study aims to evaluate the effect of two commonly used intravenous antihypertensive agents - nicardipine and sodium nitroprusside - on lung ventilation-perfusion (V/Q) distribution in patients with acute respiratory failure complicated by hypertension. Electrical Impedance Tomography (EIT) will be used for noninvasive monitoring of pulmonary ventilation and perfusion distribution before and after drug administration.

The study will compare the changes in V/Q ratio, oxygenation index, and hemodynamic variables after administration of the two drugs. The findings are expected to provide evidence for the optimal antihypertensive strategy in critically ill patients with respiratory failure and to clarify whether specific vasodilators exacerbate or improve ventilation-perfusion mismatch.

Conditions

  • Acute Respiratory Failure (ARF)
  • Hypertension
  • Pulmonary Perfusion Imbalance
  • Aortic Dissection (Subset)

Interventions

DRUG

Sodium Nitroprusside

Continuous intravenous infusion of sodium nitroprusside for blood pressure reduction in acute respiratory failure. The drug is prepared in 5% dextrose solution and administered at an initial rate of 0.3 µg/kg/min, titrated up to 2 µg/kg/min as needed to maintain target mean arterial pressure (MAP 65-85 mmHg). Each infusion period lasts 30 minutes under stable mechanical ventilation. Hemodynamic parameters, arterial blood gases, and electrical impedance tomography (EIT) data are recorded at Baseline, 30 min, and 60 min. A washout phase is observed before crossover to the second intervention.

DRUG

Nicardipine

Continuous intravenous infusion of nicardipine for blood pressure control during mechanical ventilation. The infusion begins at 1 mg/h and is titrated up to 5 mg/h according to real-time blood pressure monitoring to maintain target MAP 65-85 mmHg. Each infusion period lasts 30 minutes. Electrical impedance tomography (EIT) is used to record ventilation-perfusion matching, dead-space, and shunt fraction at Baseline, 30 min, and 60 min. After completion, a 30-minute washout period or until baseline hemodynamics are restored precedes the next crossover phase.

Sponsors & Collaborators

  • First Affiliated Hospital of Wannan Medical College

    lead OTHER

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-30
Primary Completion
2027-07-30
Completion
2027-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07603037 on ClinicalTrials.gov